Citations

Clear

2429 citation(s) found for "Shah, SS".

816: NEUROLOGICAL OUTCOMES FOLLOWING ECPR VS CONVENTIONAL CPR: SYSTEMATIC REVIEW AND META-ANALYSIS
Jena, Anek , Singh, Aditya, Merchant, Kiran, Banker, Himanshi , Sarangi, Swapna , Shah, Syed Hamza, Antar, Mohamed, Ferreira, Esteban Rodriguez, Rios, Anthony Navarrete, Bordini, Joao

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001185260.74333.66 Get It

140: PROGNOSTIC VALUE OF BODY COMPOSITION IN HEART TRANSPLANT RECIPIENTS: A REVIEW AND META-ANALYSIS
Merchant, Kiran, Antar, Mohamed, Ferreira, Esteban Rodriguez, Jena, Anek , Sarangi, Swapna , Banker, Himanshi , Ghosh, Saptarshi, Rios, Anthony Navarrete, Singh, Aditya, Shah, Syed Hamza, Bordini, Joao, Kumar, Uroosa

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001182556.15437.19 Get It

139: PREOPERATIVE PAPI PREDICTS RIGHT VENTRICULAR FAILURE IN LVAD RECIPIENTS: A REVIEW AND META-ANALYSIS
Singh, Aditya, Merchant, Kiran, Antar, Mohamed, Shah, Syed, Sarangi, Swapna , Banker, Himanshi , Ferreira, Esteban Rodriguez, Ghosh, Saptarshi, Rios, Anthony Navarrete, Bordini, Joao, Jena, Anek

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001182552.79450.e5 Get It

138: RENAL PROTECTION WITH AMINO ACID INFUSION AFTER CARDIAC SURGERY: REVIEW AND META-ANALYSIS OF RCTS
Jena, Anek , Singh, Aditya , Merchant, Kiran, Antar, Mohamed, Ferreira, Esteban Rodriguez, Rios, Anthony Navarrete, Banker, Himanshi , Sarangi, Swapna , Shah, Syed Hamza, Kumar, Uroosa, Ghosh, Saptarshi

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001182548.24051.da Get It

Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis
Gan, Can, Lai, Enjiang, Tai, Yang, Chen, Shuai, Zhao, Chong, Dai, Wenting , Yang, Zhu, Li, Bei , Lan, Tian, Xiao, Yang, Guo, Yangkun, Chen, Jiaxin , Wei, Bo, Cao, Sheng , Liu, Mengfei, Tacke, Frank, Tang, Chengwei, Shah, Vijay H. , Yu, Haopeng, Wang, Fei, Huang, Zhiyin , Gao, Jinhang, Gao, Jinhang , Gao, Jinhang , Lai, Enjiang, Tai, Yang, Lan, Tian, Xiao, Yang, Guo, Yangkun, Wei, Bo , Che, Zhaodi , Tacke, Frank , Tang, Chengwei , Yu, Haopeng

Mayo Clinic

Journal of Clinical Investigation | March 17, 2026 | Volume: 136 | Issue: 11 | Pages: No page available

10.1172/jci196730 | PMID 41842990 Get It

Cellular and molecular heterogeneity in the liver has been increasingly recognized to drive liver fibrosis progression, but the particular events that occur initially in response to liver injury and trigger immune cell recruitment remain unclear. Here, we identify epigenetically aberrant liver sinusoidal endothelial cells (LSECs) as key players in this process. Mechanistically, the epigenetic readers like bromodomain-containing protein 4–dependent (BRD4-dependent) super enhancers (SEs) activate proinflammatory genes, including promyelocytic leukemia (PML). The PML protein, in turn, binds BRD4 and amplifies proinflammatory angiocrine signaling through phase separation–dependent SE activation via PML/BRD4 condensate formation. In mouse models, LSEC-specific depletion of the PML/BRD4 complex mitigates liver inflammation and fibrosis. Single-cell RNA-seq reveals that epigenetically aberrant LSECs exhibit a reprogrammed proinflammatory angiocrine landscape in mouse fibrotic livers. TIMP1 + LSECs promote the recruitment of CD63 + monocyte–derived macrophages (MoMFs) during liver fibrosis progression. Thereby, PML/BRD4 in LSECs governs inflammatory immune cell recruitment in liver fibrosis. Pharmacological BRD4 inhibition or epigenetic PML-SE repression alleviates liver inflammation and fibrosis. In conclusion, PML/BRD4-mediated SE activation via phase separation drives proinflammatory angiocrine signaling in LSECs, initiating the inflammatory cascade and subsequent immune cell recruitment during liver fibrosis.
Second-Generation and Off-the-Shelf CAR Platforms: Emerging Cardiovascular Implications of Next-Generation Cellular Immunotherapies
Thukral, Jatin, Moudgil, Pyush, Mann, Abhay, Goyal, Tanish, Sindhwani, Ninaad, Shah, Riya Kaushal, Chandani, Kanishka Uttam, Kaur, Harbir, Thukral, Nikhil, Agrawal, Siddharth , Frishman, William H., Aronow, Wilbert S., Thukral, Jatin, Kaur, Harbir, Thukral, Nikhil, Raval, Maharshi , Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | March 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001237 | PMID 41837781 Get It

Chimeric antigen receptor (CAR)-based therapies have become an integral part of modern cancer care, delivering durable responses in patients with otherwise refractory hematologic malignancies. As their use has expanded, it has become increasingly clear that these immune-based treatments exert important effects on the cardiovascular system. Rather than reflecting isolated cardiac injury, CAR-associated cardiovascular complications arise from a broader inflammatory process in which immune activation, cytokine release, endothelial dysfunction, and myocardial stress are closely interconnected. Pro-inflammatory mediators such as interleukin-6, interleukin-1β, tumor necrosis factor-α, and interferon-γ play central roles in shaping these responses, particularly during cytokine release syndrome. From a clinical perspective, cardiovascular manifestations often include hypotension, arrhythmias, and transient reductions in left ventricular function, with more severe presentations occurring in patients who develop high-grade inflammatory toxicity. At the same time, advances in immune engineering are reshaping how these platforms are viewed, extending their relevance beyond toxicity alone. Preclinical studies now suggest that CAR-based approaches may be adapted to modulate cardiac fibrosis and promote myocardial repair, highlighting a potential shift from purely oncologic applications toward broader cardiovascular benefit. Placing these developments within a cardio-oncology framework emphasizes the need for careful cardiovascular assessment, longitudinal monitoring, and close collaboration between specialties.
Germline genetic variants and epilepsy surgery response: individual-participant pooled analysis of 269 patients
Ivaniuk, Alina, Bajaj, Sunanjay , Bosselmann, Christian M, Koh, Hyun Yong, Pestana-Knight, E, Zhang, Xiaoming, Bingaman, William, Najm, Imad, Shah, Manish N., Tandon, N., Allmen, Gretchen Von , Lhatoo, Samden D. , Tatum, William, Freund, Brin , Miller, Kai J. , Wirrell, Elaine, Coryell, J., Schreiber, John, Perry, Scott, Lal, Dennis , Ivaniuk, Alina , Ivaniuk, Alina , Boßelmann, Christian M. , Koh, Hyun Yong , Pestana‐Knight, Elia , Bingaman, William , Najm, Imad , Shah, Manish N. , Tatum, William, Wirrell, Elaine , Fine, Anthony L. , Coryell, Jason , Schreiber, John R. , Perry, Scott

Mayo Clinic

No container title available | March 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.10.26347961 Get It

Abstract Background Genetic testing is increasingly used in presurgical evaluation, but the yield of resection across germline genetic epilepsies remains uncertain. Methods We conducted a systematic review of MEDLINE (PubMed) and Scopus and added cases from three institutional cohorts and the Pediatric Epilepsy Research Consortium (PERC) databases, including individuals with pathogenic/likely pathogenic germline variants besides tuberous sclerosis and neurofibromatosis who underwent resection or laser ablation. Etiologies were grouped into biologically informed categories (GATORopathies, vascular, overgrowth, CNVs, channelopathies, synaptopathies, other). Primary outcome was seizure freedom (Engel I) at last follow-up. Group comparisons used Fisher’s exact and Kruskal–Wallis tests (α=0.05; Bonferroni when applicable). Prespecified sensitivity analyses stratified by lesional status, excluded GATORopathies, and restricted to literature-only cases. Results We included 223 literature cases (64 studies), 35 institutional cases, and 11 PERC cases (n=269). Median follow-up was 24 months (IQR 12–48.0). Seizure freedom was achieved in: vascular disorders 14/19 (73.6%), GATORopathies 79/120 (67.5%), CNVs 18/31 (66.7%), overgrowth 7/13 (53.8%), other 16/25 (41.7%), channelopathies 13/43 (33.3%), and synaptopathies 4/18 (22.2%) (overall p<0.001). Among cases with known imaging, 208/253 (82.2%) had epileptogenic MRI lesions, including 64% of channelopathies and 80% of the synaptopathies. In univariate contrasts (each category vs all others), odds of seizure freedom were higher for vascular disorders (2.66-fold, 95% CI 0.87–9.72) and GATORopathies (2.46-fold, 95% CI 1.46–4.18), and lower for synaptopathies (∼4.2-fold lower, OR 0.24, 95% CI 0.05– 0.78) and channelopathies (∼4.5-fold lower, OR 0.22, 95% CI 0.09–0.48). Direction and magnitude were consistent across prespecified sensitivity analyses (lesional-only, literature-only, exclusion of GATORopathies). Conclusions Resective surgeries can be effective in germline genetic epilepsies, but outcomes vary by pathway. Disorders with discrete, lesional substrates (GATORopathies, vascular) show the highest likelihood of seizure freedom, whereas channelopathies and synaptopathies, despite the presence of MRI lesions, have substantially lower yields even in lesional cases. Prospective, genotype-aware surgical registries with standardized reporting (EEG, imaging, pathology) and time-to-event outcomes are needed to refine the selection of surgical candidates and quantify seizure and non-seizure-related outcomes.
Expanding the Motor Band Sign in Motor Neuron Disease Using 7T MRI : Visualization of Cortical Layer‐Dependent Iron Deposition in the Primary Motor Cortex
Shah, Jaimin, Sledge, Hanna J, Virador, Gabriel M. , Middlebrooks, Erik H. , Shah, Jaimin , Zhou, Xiangzhi , Virador, Gabriel, Parizadeh, Donna , Middlebrooks, Erik H , Oskarsson, Björn , Heckman, Michael G. , Sledge, Hanna J., Parizadeh, Donna, Parizadeh, Donna

Mayo Clinic

Muscle & Nerve | March 8, 2026 | Volume: 73 | Issue: 6 | Pages: 996-1004

10.1002/mus.70179 | PMID 41792976 Get It

ABSTRACT Introduction/Aims There are no established biomarkers of upper motor neuron degeneration to aid in the diagnosis of motor neuron disease (MND). This study examines the diagnostic value of the motor band sign as a marker of upper motor neuron degeneration and its relationship to clinical findings in MND. Methods Records of consecutive patients who underwent 7T magnetic resonance imaging (MRI) between October 2021 and April 2025 for evaluation of MND or other neurologic indications were retrospectively reviewed. Clinical variables and plasma neurofilament light chain (pNfL) levels were recorded. An upper motor neuron score (Mayo UMNS) was derived from reflex scores. Blinded MRI review assessed the degree of susceptibility‐weighted imaging (SWI) hypointensity in the hand, foot, and bulbar motor cortex regions. Results An MBS was observed in 100 of 117 (85.5%) MND patients and in 16 (15.5%) patients with non‐MND diagnoses, corresponding to a sensitivity of 85.5% (78.0%–90.7%) and 84.5% (76.2%–90.2%) specificity. The MBS in 78 MND patients (70.9%) preferentially involved the middle and deep cortical layers, giving a trilaminar appearance, while only one non‐MND patient had this finding. Mayo UMNS ( β = 0.89, p < 0.001), pNfL ( β = 0.63, p = 0.033), and age at evaluation ( β = 0.68, p = 0.027) were independently associated with the summed SWI score. Discussion The 7T MRI MBS is a sensitive and specific marker for MND that complements established clinical evaluation. Using 7T, a trilaminar appearance of the motor cortex, reflecting known histopathological changes, can be visualized and may be specific to MND.
Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neuro
Sorenson, Eric J. , Heitzman, Daragh, Lee, Ikjae , Jang, Grace E. , Elman, Lauren , Habib, Ali A. , Wymer, James , Hayat, Ghazala , Fernandes, J Americo M, Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Ej, Kasarskis, Kisanuki, Yasushi, Lomen-Hoerth, Catherine, Walk, David , Johnston, Wendy S, Diaz, Frank, Maragakis, Nicholas J, Paganoni, Sabrina, Shah, Jaimin, Zinman, Lorne, Heiman-Patterson, Terry, Jawdat, Omar, Fournier, Christina N, Pulley, Michael , Scelsa, Stephen N. , Shoesmith, Christen , Sherman, Alex, Hoover, Benjamin N, Yun, Rebecca, Cheung, Ken, Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Maragakis, Nicholas J. , Sorenson, Eric , Gwathmey, Kelly , Walk, David , Paganoni, Sabrina , Shah, Jaimin , Pulley, Michael T , Simmons, Zachary , Maragakis, Nicholas , Wymer, James, Goutman, Stephen A. , Kasarskis, Edward J. , Lomen‐Hoerth, Catherine , Johnston, Wendy , Diaz, Frank , Oskarsson, Björn , Zinman, Lorne , Heiman‐Patterson, Terry , Fournier, Christina , Simmons, Zachary , Hoover, Benjamin N.

Mayo Clinic

Muscle & Nerve | March 8, 2026 | Volume: 73 | Issue: 6 | Pages: 976-983

10.1002/mus.70192 | PMID 41772409 Get It

ABSTRACT Background Primary lateral sclerosis (PLS) is an ultrarare upper motor neuron syndrome with a prognosis unique from classical ALS. The study of PLS is complicated by its rarity and the difficulty distinguishing PLS from ALS. We present data from a 1‐year prospective follow‐up study on PLS and efforts to distinguish it from ALS. Methods Seventy‐six PLS participants enrolled in this prospective natural history study. EMG studies, blood neurofilament light chain levels (NfLs), and demographic characteristics were obtained at baseline. At 1‐year follow‐up, repeat EMG studies were conducted to determine which participants fulfilled criteria for ALS. Baseline characteristics were then compared to determine features that predict reclassification. Results Seventy participants completed 1‐year follow‐up. Five of the 70 were reclassified to ALS (7.1%). Those reclassified had higher trends in baseline blood NfL levels (91.4 vs. 34.0 pg/mL, p = 0.13) and shorter symptom duration (39 vs. 69 months in the PLS group, p = 0.15). Reclassification was noted in both probable and definite PLS participants. All cases with a symptomatic duration of less than 2 years retained the PLS phenotype (5 of 5). NfL levels over 90 pg/mL predicted reclassification with 94% specificity and 60% sensitivity. No other features predicted reclassification to ALS. Conclusions In our population, reclassification of PLS to ALS occurred at a low frequency at 1 year follow‐up (7.1%). Baseline NfL was the strongest predictor in differentiating UMN dominant ALS from PLS at 1‐year follow‐up. Based on our data, we propose EMG and NfL criteria for enrollment in future PLS trials.